In addition to my above post, the skin explant study announced on 8th of September, showed that BTX 1801 eradicates MRSA.
- In addition, it reported that MRSA do not develop antibiotic resistance to cannabinoids.
- Therefore, BTX 1801 may be useful in cases where repeated dosages of bactroban are needed, such as in dialysis patients.
- If BTX 1801 can be used to manage staph in such patients, it would be superior to Bactroban in that antibiotic resistance would not occur.
- Bactroban is not recommended for repeated use, so clinicians are in a conundrum about what to do when patients require ongoing treatment for non-MRSA and other bacterial infections.
- BTX 1801 therefore could fill this need now, if it were approved e.g. by the FDA/TGA, because it has been shown to eradicate staph and it does not lead to antibiotic resistance.
On the 11/11 it was announced that the FDA has cleared the development path for BTX 1801, so positive news could come at any time.
There is a lot to be positive about re. BTX 1801.
Bot Chart, page-4540
-
- There are more pages in this discussion • 9,292 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.005(1.32%) |
Mkt cap ! $696.8M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.5¢ | 37.5¢ | $4.475M | 11.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 37310 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 54981 | 2 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |